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ABSTRACT
Background: Viral load peak and immune activation occur shortly after exposure during acute 
or early HIV infection (AEHI). We aimed to define the benefit of early start of antiretroviral 
treatment (ART) during AEHI in terms of immunological recovery, virological suppression, and 
treatment discontinuation.
Setting: Patients diagnosed with AEHI (Fiebig stages I-V) during 2008-2014 from an analysis of 
20 Italian centers. 
Methods: This was an observational, retrospective, and multicenter study. We investigated the ef-
fect of early ART (defined as initiation within 3 months from AEHI diagnosis) on time to virolog-
ical suppression, optimal immunological recovery (defined as CD4 count ≥ 500/µL, CD4 ≥ 30%, 
and CD4/CD8 ≥ 1), and first-line ART regimen discontinuation by Cox regression analysis. 
Results: There were 321 patients with AEHI included in the study (82.9% in Fiebig stage III-V). 
At diagnosis, the median viral load was 5.67 log10 copies/mL and the median CD4 count was 456 
cells/µL. Overall, 70.6% of patients started early ART (median time from HIV diagnosis to ART 
initiation 12 days, IQR 6-27). Higher baseline viral load and AEHI diagnosis during 2012-2014 
were independently associated with early ART. HBV co-infection, baseline CD4/CD8 ≥ 1, lower 
baseline HIV-RNA, and AEHI diagnosis in recent years (2012-2014) were independently associ-
ated with a shorter time to virological suppression. Early ART emerged as an independent predic-
tor of optimal immunological recovery after adjustment for baseline CD4 (absolute and percent-
age count) and CD4/CD8 ratio. The only independent predictor of first-line ART discontinuation 
was an initial ART regimen including > 3 drugs. 
Conclusions: In a large cohort of well-characterized patients with AEHI, we confirmed the ben-
eficial role of early ART on CD4+ T-cell recovery and on rates of CD4/CD8 ratio normalization. 
Moreover, we recognized baseline CD4/CD8 ratio as an independent factor influencing time to 
virological response in the setting of AEHI, thus giving new insights into research of immunolog-
ical markers associated with virological control. 
Keywords: acute/early HIV infection; early antiretroviral treatment; optimal immunological re-
covery; intensified antiretroviral regimen
INTRODUCTION
Acute or early HIV infection (AEHI) is a brief, rarely diagnosed, but critical phase of HIV infec-
tion. AEHI is known to be characterized by very high levels of HIV-RNA load and several studies 
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have shown that HIV transmission is greatly amplified during AEHI, thus defining a relevant 
contribution of this phase to onward HIV transmission [1, 2]. During AEHI, long-lived reser-
voirs of virus are established early on, representing a major obstacle to achieving HIV eradication 
[3, 4]. Moreover, immune dysregulation is rapidly detected after viral infection contributing to 
over-heightened immune activation [5, 6]. 
Several studies assessing antiretroviral treatment (ART) during AEHI have suggested beneficial 
effects on biological markers of disease progression, such as reduction of viremia [7], lower viral 
set point [8], lower probability of transmission [9, 10], and a reduced number of infected cells 
limiting the size of the latent pool of HIV-1-infected CD4+ T cells [11, 12]. Moreover, it has been 
shown that starting ART in the initial phase of infection might allow for the preservation of the 
immune system, and specifically of: (1) the CD4+ T-cell count and CD4/CD8 ratio [13-15]; (2) 
HIV-specific immune responses, preserving the ability to control viral replication [16]; (3) higher 
levels of mucosal and systemic Th17 cells; (4) lower levels of B-lymphocyte activation, and (5) 
reconstitution of the NK phenotype [12, 17 ,18]. Despite the fact that evidence from multiple 
studies strongly supports the benefit of early ART in AEHI [19-20], the optimal ART strategy 
to achieve rapid viral suppression, optimal immune recovery, and longer durability of regimens 
needs to be clarified. 
Thus, we used retrospective data from a large national cohort to assess whether an early start of 
ART during AEHI is associated with an optimal immunological recovery, the timing of virologi-
cal suppression, and the risk of discontinuation of first-line antiretroviral regimen.
PATIENTS AND METHODS
Study Design
This was a retrospective, observational, multicenter cohort study including patients with AEHI 
diagnosed between  January 1, 2008 and December 31, 2014 at 20 Italian centers included in a 
national network (INACTION - Italian Network on AcuTe HIV InfectiON). 
Inclusion Criteria
Cases of AEHI were identified by a retrospective analysis of clinical files and databases of each 
participating center. Patients were included in the study if they presented at least 1 criterion for 
HIV infection diagnosis (A) and concomitantly at least 1 criterion for acute or early HIV infec-
tion (B). Criteria for (A) were 1) p24 reactivity, 2) HIV-RNA and/or HIV-DNA PCR detectable 
viral load; Criteria for (B) were 1) negative HIV-antibodies or low titer reactivity in an ELISA 
third (or further) generation assay, 2) less than 3 positive bands in a Western blot test includ-
ing p24, gp160/gp120, or gp41, 3) less than 2 positive bands in a RIBA test including reactivity 
for gp41. Patients with AEHI were classified according to Fiebig criteria [21]; only patients with 
Fiebig stages I-V were included, while those with Fiebig stage VI or with no available Fiebig stage 
were excluded. 
Type and Timing of Antiretroviral Treatment (ARV)
The type of regimen (ie, the number of agents and the drug class included) and the follow-up 
schedule were selected by a single clinician, according to national or local guidelines. Patients 
who started any ART regimen within 3 months of the AEHI diagnosis were classified as ear-
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ly ART group (Early ART), while the other patients were included in the late ART group (Late 
ART).
Endpoints and Definitions
The primary endpoint was the optimal immune recovery defined as a composite endpoint includ-
ing the first occurrence of CD4 count ≥ 500/µL, CD4/CD8 ratio ≥1, and CD4 ≥ 30% after ART 
initiation [22].
The secondary endpoints were the rate of virological suppression and the risk of discontinuation 
of a first-line antiretroviral regimen. Virological suppression was defined as reaching HIV-RNA 
< 50 copies/mL. Discontinuation of first-line antiretroviral regimen was defined as the change of 
any drug in the regimen, new drugs added to the regimen, or ending the regimen.
Data Collecting
Demographical (age at diagnosis, gender), epidemiological (mode of HIV transmission, date of 
last negative/undetermined HIV test, date of first reactive HIV test), clinical (symptoms at pre-
sentation, CDC stage, comorbidities), and laboratory (plasma HIV-RNA load, CD4 and CD8 
T-cell count) data were assessed at the time of AEHI diagnosis. Follow-up was carried out un-
til June 30, 2016 or the last available visit. During follow-up, we assessed viro-immunological 
parameters, clinical or laboratory adverse events, and hospital admissions or death occurring 
between AEHI diagnosis and the end of follow-up. The first-line and subsequent ART regimens 
were recorded since AEHI diagnosis (baseline, BL) occurred until December 31, 2014. 
Ethical Approval
The study was approved by the Ethics Committee (EC) of Monza-Brianza for San Gerardo Hospi-
tal (coordinating center) in June 2014 and then by the EC of each participating center. 
Statistical Analysis
Categorical variables were described as absolute and percentage frequency; continuous variables 
with normal distribution were described as mean and standard deviation (SD), whereas those 
with non-normal distribution were described as median and interquartile range (IQR). Char-
acteristics of Early ART and Late ART groups were compared using Student’s t test or Mann 
Whitney U-test and chi-square test or Fisher test, as appropriate. Logistic regression analysis was 
performed to identify factors associated with early ART initiation. Incidence and predictors of 
time to virological suppression, time to first-line regimen discontinuation, and time to optimal 
immunological recovery were explored by Kaplan-Meier curves and Cox regression analysis. In 
all these models, variables showing a significant association with the outcome at univariate anal-
ysis were then evaluated in a multivariate model. A  2-tailed P-value < 0.05 was considered to be 
statistically significant.
All statistical analyses were performed using SPSS version 13.0 software package (SPSS Inc., Chi-
cago, IL).
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RESULTS
Population Characteristics
Overall, 321 patients were analyzed (Table 1). Most were males (n = 276, 86%) and acquired HIV 
infection through MSM intercourses (n = 184, 57.3%) at a median age of 37 years (IQR 30-46). Pa-
tients reported a median time from the last negative HIV test of 6.8 months (IQR 3.35-16.4). 
Table 1. Population characteristics at the time of AHI diagnosis (n = 321) and comparison 
of Early (< 3 months from AHI diagnosis) and Late (> 3 months) ART initiation groups 
(n = 296).
Total (n = 321) Early ART (n = 209) Late ART (n = 87)
N (%) or median 
(IQR)
N (%) or median 
(IQR)
N (%) or median 
(IQR)
P
Age, years 37 (30-46) 38 (30-46) 38 (31-46) 0.580
Male gender 276 (86) 181 (86.6) 75 (86.2) 1.000
Risk factor:
    Heterosexual
    Homo/bisexual
    IDU
    Other/unknown
 
92 (28.7)
184 (57.3)
14 (4.4)
31 (9.7)
57 (27.3)
126 (60.3)
8 (3.8)
18 (8.6)
30 (34.5)
47 (54)
1 (1.1)
9 (10.3)
0.369
HBsAg+ 11 (3.4) 8 (3.8) 2 (2.3) 0.679
HCV coinfection 15 (4.7) 8 (3.8) 4 (4.6) 0.613
Months from last negative HIV 
test
6.8 (3.35-16.4) 7.1 (2.9-23.6) 5.9 (3.4-12) 0.065
Year of diagnosis < 0.001
2008-2011 106 (33) 46 (22) 49 (56.3)
2012-2014 215 (67) 163 (78) 38 (43.7)
Fiebig stage:
    I
    II
    III
    IV
    V 
14 (4.4)
41 (12.8)
54 (16.8)
116 (36.1)
96 (29.9)
7 (3.3)
30 (14.4)
38 (18.2)
71 (34)
63 (30)
6 (6.9)
9 (10.3)
12 (13.8)
36 (41.4)
24 (27.6)
0.370
Symptomatic acute HIV infection 227 (70.7) 158 (75.6) 52 (59.8) 0.012
    Fever 177 (55.1)
    Lymphadenopathy 78 (24.3)
    Rash 55 (17.1)
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    Pharyngitis 41 (12.8)
    Diarrhea 26 (8.1)
Headache/meningism 15 (4.7)
    Other 89 (27.7)
CDC Stage:
    A
    B
    C
    Unknown
254 (79.1)
19 (5.9)
5 (1.6)
43 (13.4)
3 (1.4) 1 (1.3) 0.866
Concomitant STD 30 (9.3) 19 (9.1) 8 (9.2) 1.000
Baseline laboratory results:
    WBC, cells/µL 5800 (4257-7345)
    Lymphocytes, cells/µL 2059 (1350-2900)
    Platelets, cells/µL 196000 (156000-
229500)
    Hemoglobin, g/dL 14.1 (13.1-15)
    AST, UI/L 29 (21-47)
    ALT, UI/L 37 (25-63)
    CD4, cells/µL 456 (331-605) 435 (300-574) 478 (371-599) 0.039
          > 500 122 (38) 25 (12) 3 (3.4) 0.014
          200-500 144 (44.9)
          < 200 28 (8.7)
          Unknown 27 (8.4)
    CD4% 21.7 (14.8-30) 21 (13.8-29) 23 (16-30) 0.369
    CD4% ≥ 30% 74 (23.1) 46 (22) 19 (21.8) 0.025
    CD8, cells/µL 1031 (639.5-1833) 1027 (608-1772) 1062 (721-1715) 0.675
    CD4/CD8 0.4 (0.22- 0.7) 0.4 (0.2-0.67) 0.43 (0.26-0.80) 0.659
    CD4/CD8 ≥ 1 30 (9.3) 19 (9.1) 7 (8) 0.257
    HIV-RNA, log10 copies/mL 5.67 (5.00-6.36) 5.96 (5.19-6.60) 5.67 (4.99-6.36) < 0.001
ART initiation during follow up 296 (92.2)
Early (< 3 months from BL) ART 
initiation
209/296 (70.6)
Pathogens and Immunity - Vol 5, No 1
www.PaiJournal.com
15
First ART regimen including:
    NRTI
    NNRTI
    PI
    InSTI
    Entry inhibitor
206 (98.6)
21 (10)
165 (78.9)
93 (44.5)
24 (11.5)
86 (98.9)
38 (43.7)
41 (47.1)
11 (12.6)
2 (2.3)
1.000
< 0.001
< 0.001
< 0.001
0.020
First line ART including > 3 
drugs
81 (38.8) 4 (4.6) < 0.001
Abbreviations: AHI Acute HIV Infection; IDU Intravenous Drug User; CDC Centers for Disease Control; 
WBC White Blood Cells; STD Sexually Transmitted Diseases; ART Antiretroviral Therapy, NRTI Nucleo-
side Reverse Transcriptase Inhibitor; NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors; PI Prote-
ase Inhibitor; InSTI Integrase Strand Transfer Inhibitor; BL Baseline.
In our population, most patients (n = 215, 67%) were diagnosed with AEHI in recent years of 
observation (ie, 2012-2014). 
At the time of AEHI diagnosis, median plasma HIV-RNA load was 5.67 log10 copies/mL (IQR 
5.00-6.36), with a median absolute CD4 count of 456 (IQR 331-605) cells/µL, a median percent-
age CD4 count of 21.7% (IQR 14.8-30), and a median CD4/CD8 ratio of 0.4 (IQR 0.22-0.7).
Symptomatic AEHI was observed in 70.7% (n = 227) of patients. Of note, an AIDS-defining event 
was observed in 5 (1.6%) patients at the time of AEHI diagnosis (3 patients with esophageal can-
didiasis and 2 with Pneumocystis jirovecii pneumonia). 
At the time of AEHI diagnosis, 17.1% (n = 55) of patients were classified in Fiebig stages I-II. Pa-
tients in Fiebig stages I-II had a higher viral load (median 6.11 vs 5.63 log10 copies/mL, P = 0.001) 
and a higher percentage of CD4 cells (median 27% vs 21%, P = 0.003) when compared to Fiebig 
III-V, but the absolute number of CD4 was similar in the 2 groups (median 468 vs 454 cells/µL, 
P = 0.324). A higher proportion of HBsAg+ patients was observed in the Fiebig I-II group (9.1% 
vs 2.3%, P = 0.034).
ART Initiation During Follow-Up and Comparison of Early ART and Late ART Groups
During follow-up, ART was started in 92.2% (n = 296) of patients, of whom 70.6% (n = 209) start-
ed within 3 months (Early ART) (Table 1). In the overall population, the median time from AEHI 
diagnosis to ART initiation was 23 days (IQR 7-148). However, it was 12 days (IQR 6-27) in the 
subgroup of patients who started early versus 351 (IQR 221-762) in those who started late. Nearly 
all patients (n = 292, 98.6%) were prescribed nucleoside reverse transcriptase inhibitors (NRTI) in 
their first ART regimen, associated with a protease inhibitor (PI) in most cases (n = 206, 69.6%); 
integrase inhibitors (InSTI) were prescribed in 104 (35.1%) patients. First-line ART consisted of 
more than 3 drugs in 28.7% (n = 85) of patients.
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A comparison of characteristics of patients with Early ART or Late ART is represented in Table 
1. Patients in the Early ART group more frequently had symptomatic AEHI (75.6% [n = 158] vs 
59.8% [n = 52], P = 0.012) and had lower CD4+ T-cell counts (median 435 [IQR 300-574] vs 478 
[371-599] cells/µL, P = 0.039) as well as higher baseline HIV-RNA (median 5.96 [IQR 5.19-6.60] 
vs 5.67 [IQR 4.99-6.36] log10 copies/mL, P < 0.001). Patients diagnosed after 2012 were more 
likely to start ART early (78% [n = 163] vs 43.7% [n = 38] than in the previous period, P < 0.001); 
moreover, in the Early ART group, regimens including more than 3 drugs were prescribed more 
frequently (38.8% [n = 81] vs 4.6% [n = 4], P < 0.001). In addition, the preferred antiretroviral reg-
imen was PI-based (78.9% [n = 165] vs 47.1% [n = 41], P < 0.001) or InSTI-based (44.5% [n = 93] 
vs 12.6% [n = 11], P < 0.001) rather than non-nucleoside reverse transcriptase inhibitor (NN-
RTI)-based (10% [n = 21] vs 43.7% [n = 38], P < 0.001).
We evaluated factors associated with early ART initiation by logistic regression analysis (Table 
2). At multivariate analysis, higher plasma HIV-RNA load (adjusted odds ratio, aOR 1.76 per 1 
log10 increase [95% confidence intervals, CI 1.29-2.40], P < 0.001) and more recent years of AEHI 
diagnosis (years 2012-2014 aOR 4.43 [95% CI 2.41-8.12] when compared to 2008-2011, P < 0.001) 
were independently associated with early ART initiation. This was after adjustment for symptom-
atic acute infection and CD4 lymphocyte number. Fiebig stage was not associated with early ART 
initiation.
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Table 2. Factors associated with early ART initiation (logistic regression analysis)
Univariate analysis Multivariate analysis
OR (95% CI) P aOR (95% CI) P
Age, years (per 10 years increase) 1.07 (0.84-1.36) 0.578
Male gender 1.03 (0.50-2.14) 0.928
Risk factor:
    Heterosexual
    Omo/bisexual
    IDU
    Other/unknown
Ref.
1.41 (0.81-2.46)
4.21(0.50-35.27)
1.05 (0.42-2.63)
0.224
0.185
0.912
HBsAg+ 1.72 (0.35-8.29) 0.497
HCV coinfection 0.80 (0.23-2.74) 0.725
Months from last negative HIV test, 
(per 1 month increase)
1.01 (1.00-1.02) 0.157
Fiebig stage:
    I
    II
    III
    IV
    V
0.44 (0.14-1.46)
1.27 (0.52-3.06)
1.20 (0.54-2.69)
0.75 (0.40-1.39)
Ref.
0.181
0.595
0.646
0.364
Symptomatic acute HIV infection 2.38 (1.33-4.24) 0.003 1.97 (1.00-3.90) 0.051
CDC stage C 1.29 (0.13-12.60) 0.828
Concomitant STD 0.99 (0.41-2.34) 0.977
Baseline laboratory results:
    CD4, cells/µL (per 100 cells/µL 
increase)
0.90 (0.81-1.00) 0.044 0.92 (0.82-1.04) 0.921
    CD8, cells/µL (per 100 cells/µL 
increase)
1.00 (0.98-1.03) 0.674
    CD4/CD8 ≥ 1 1.06 (0.42-2.64) 0.899
    HIV-RNA, log10 copies/mL (per 
1log10 copies/mL increase)
1.88 (1.43-2.46) < 0.001 1.76 (1.29-2.40) < 0.001
Year of diagnosis, 2012-2014 vs 
2008-2011
1.65 (1.42-1.92) < 0.001 4.43 (2.41-8.12) < 0.001
Abbreviations: IDU Intravenous Drug User; CDC Centers for Disease Control; STD Sexually Transmitted 
Diseases.
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Optimal Immunological Recovery
At the time of first-line regimen initiation, only 11 (3.4%) patients had optimal immunological 
status (ie, CD4 ≥ 500/µL plus CD4 ≥ 30% plus CD4/CD8 ratio ≥ 1). Of the remaining patients, 
187 (58.3%) had follow-up immunological data. Optimal immunological recovery was achieved 
by 95 (50.8%) patients during a median follow-up of 35 weeks (IQR 15-85), with an incidence of 
3.7 per 100 person-months of follow-up (PMFU). The Early ART group had a higher probability 
of optimal immunological recovery; at Kaplan Meier analysis the estimated incidence of optimal 
immunological recovery at 48 weeks was 39% in the Early ART group vs 22.5% in the Late ART 
group (P = 0.002 at log rank test) (Figure 1A).
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Figure 1. Kaplan Meier estimates of time to (A) optimal immunological recovery, (B) virological suppres-
sion and (C) first-line regimen discontinuation in Early versus Late ART group.
We evaluated predictors of time to optimal immunological recovery by Cox regression analysis 
(Table 3). At multivariate analysis, early ART (HR 1.84 [95% CI 1.04-3.27], P = 0.036) confirmed 
an independent association with a higher probability of optimal immunological recovery after 
adjustment for Fiebig stage, the first ART regimen including > 3 drugs, calendar year, and baseline 
immunological status (ie, absolute and percentage CD4 count, CD4/CD8 ratio). 
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Table 3. Predictors of time to optimal immunological recovery defined as: CD4 ≥ 500cells/
µL, CD4% ≥ 30% and CD4/CD8 ≥ 1 (Cox regression analysis) (n = 187)
Univariate analysis Multivariate analysis
HR (95% CI) P aHR (95% CI) P
Age, years (per 10 years increase) 1.08 (0.88-1.33) 0.475
Male gender 0.95 (0.53-1.71) 0.870
Risk factor:
    Heterosexual
    Homo/bisexual
    IDU
    Other/unknown
Ref.
0.97 (0.61-1.54)
1.07 (0.37-3.08)
0.78 (0.37-1.67)
0.899
0.900
0.525
HBsAg+ 0.45 (0.11-1.82) 0.261
HCV coinfection 0.74 (0.27-2.01) 0.551
Months from last negative HIV test, 
(per 1 month increase)
1.00 (1.00-1.01) 0.300
 Fiebig stage:
    I
    II
    III
    IV
    V
1.14 (0.27-4.92)
2.38 (1.26-4.49)
2.57 (1.42-4.65)
2.07 (1.20-3.56)
Ref.
0.857
0.008
0.002
0.009
1.47 (0.33-6.63)
1.60 (0.82-3.12)
1.95 (0.97-3.90)
1.44 (0.79-2.61)
0.616
0.167
0.061
0.236
Symptomatic acute HIV infection 1.13 (0.68-1.88) 0.650
CDC Stage C 1.47 (0.20-10.61) 0.705
Concomitant STD 1.68 (0.89-3.16) 0.107
Early (< 3 months from BL) ART 
initiation
2.08 (1.30-3.32) 0.002 1.85 (1.04-3.27) 0.036
First ART regimen including:
    NRTI
    NNRTI
    PI
    InSTI
    Entry inhibitor
1.81 (0.25-13.05)
0.83 (0.51-1.34)
1.02 (0.65-1.59)
1.96 (1.20-3.21)
1.37 (0.78-2.42)
0.557
0.440
0.941
0.008
0.279
Pathogens and Immunity - Vol 5, No 1
www.PaiJournal.com
21
First ART regimen including > 3 
drugs
1.94 (1.23-3.05) 0.004 1.41 (0.84- 2.37) 0.188
Laboratory results at first ART initi-
ation:
    CD4, cells/µL (per 100cell/µL 
increase)
1.15 (1.06-1.24) 0.001 1.12 (1.02-1.23) 0.020
CD4% (per 1% increase) 1.06 (1.04-1.09) < 0.001 1.04 (1.01-1.07) 0.003
    CD8, cells/µL (per 100cell/µL 
increase)
0.98 (0.96-1.00) 0.053
    CD4/CD8 ≥ 1 4.15 (2.01-8.60) < 0.001 2.84 (1.17-6.91) 0.022
    HIV-RNA, log10 copies/mL (per 
1log10 copies/mL increase)
1.15 (0.92-1.44) 0.225
Year of diagnosis, 2012-2014 vs 2008-
2011
1.24 (1.08-1.43) 0.002 1.56 (0.90-2.68) 0.112
Abbreviations: IDU Intravenous Drug User; CDC Centers for Disease Control; STD Sexually Transmit-
ted Diseases; ART Antiretroviral Therapy; BL Baseline; NRTI Nucleoside Reverse Transcriptase Inhibitor; 
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors; PI Protease Inhibitor; InSTI Integrase Strand 
Transfer Inhibitor.
Virological Suppression After ART Initiation
Follow-up virological data were available for 259/296 (87.5%) patients starting ART. During a me-
dian follow-up of 21 weeks (IQR 12-28), virological suppression was achieved by 219 (84.6%) pa-
tients with an incidence of 15.9 per 100 PMFU. By Kaplan-Meier analysis, the estimated propor-
tion of patients achieving virological suppression after 48 weeks from ART initiation was 89.5%, 
with no significant differences between the Early ART (89.5%) and Late ART group (89.2%) 
(P = 0.159 at log rank test) (Figure 1B).
We evaluated predictors of time to virological suppression using Cox regression analysis (Table 4). 
At multivariate analysis, HBs-Ag positivity (adjusted hazard ratio, aHR 5.15 [95% CI 1.36-19.51], 
P = 0.016), CD4/CD8> 1 (aHR 4.05 [95% CI 2.012-8.16], P < 0.001), and HIV diagnosis in recent 
years vs years 2012-2014 (aHR 1.90 [95% CI 1.07-3.39]) in years 2012-2014 when compared to 
years 2008-2011, P = 0.028] were independently associated with a higher probability of virologi-
cal suppression, while higher HIV-RNA (aHR 0.62 [95% CI 0.46-0.86] for each 1 log10 copies/mL 
increase, P = 0.003) was associated with a lower probability, after adjusting for early ART and time 
from last negative HIV test.
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Table 4. Predictors of time to virological suppression – Cox regression analysis
Univariate analysis Multivariate analysis
HR (95% CI) P aHR (95% CI) P
Age, years (per 10 years increase) 0.96 (0.85-1.09) 0.513
Male gender 0.90 (0.62-1.31) 0.582
Risk factor:
    Heterosexual
    Homo/bisexual
    IDU
    Other/unknown
Ref.
1.08 (0.80-1.45)
0.96 (0.46-2.02)
0.85 (0.52-1.39)
0.634
0.923
0.848
HBsAg+ 2.26 (1.06-4.84) 0.036 5.16 (1.36-19.51) 0.016
HCV coinfection 0.69 (0.35-1.35) 0.275
Months from last negative HIV test, 
(per 1 month increase)
1.01 (1.00-1.01) 0.009 1.01 (1.00-1.01) 0.079
Fiebig stage:
    I
    II
    III
    IV
    V
0.81 (0.41-1.64)
1.46 (0.96-2.23)
0.82 (0.55-1.24)
1.09 (0.78-1.51)
Ref.
0.563
0.077
0.355
0.618
Symptomatic acute HIV infection 1.09 (0.79-1.50) 0.612
CDC Stage C 1.30 (0.41-4.08) 0.656
Concomitant STD 0.76 (0.45-1.29) 0.311
Early (< 3 months from BL) ART 
initiation
1.23 (0.92-1.65) 0.161
First ART regimen including:
    NRTI
    NNRTI
    PI
    InSTI
    Entry inhibitor
0.75 (0.24-2.36)
0.79 (0.58-1.10)
1.06 (0.79-1.42)
1.22 (0.91-1.65)
0.94 (0.59-1.49)
0.627
0.160
0.716
0.187
0.799
First ART regimen including > 3 
drugs
1.04 (0.77-1.40) 0.807
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Laboratory results at first ART 
initiation:
    CD4, cells/µL (per 100cell/µL 
increase)
1.06 (1.00-1.13) 0.070
    CD8, cells/µL (per 100cell/µL 
increase)
0.99 (0.96-1.00) 0.165
    CD4/CD8 ≥ 1 2.31 (1.40-3.79) 0.001 4.05 (2.01-8.16) < 0.001
    HIV-RNA, log10 copies/mL (per 
1log10 copies/mL increase)
0.76 (0.64-0.90) 0.001 0.63 (0.46-0.86) 0.003
Year of diagnosis, 2012-2014 vs 
2008-2011
1.14 (1.05-1.23) 0.002 1.91 (1.07-3.39) 0.028
Abbreviations: IDU Intravenous Drug User; CDC Centers for Disease Control; STD Sexually Transmit-
ted Diseases; ART Antiretroviral Therapy; BL Baseline; NRTI Nucleoside Reverse Transcriptase Inhibitor; 
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors; PI Protease Inhibitor; InSTI Integrase Strand 
Transfer Inhibitor.
First Line ART Regimen Discontinuation 
Follow-up data on antiretroviral regimens were available for 262/296 (88.5%) patients starting 
ART. During a median follow-up of 31 weeks (IQR 12-76), the first-line regimen was discontin-
ued/switched by 148 (56.5%) patients with an incidence of 4.4 per 100 PMFU. Of 148 patients 
with first-line ART regimen discontinuation, 136 (91.9%) had modification of regimen com-
position and only 12 (8.1%) patients discontinued all ART (9 in the early and 3 in the late ART 
group). Early ART-treated patients had a higher probability of discontinuation of the first ART 
regimen; at Kaplan Meier analysis, the estimated incidence of ART discontinuation at 48 weeks 
was in 56.6% in the Early ART group versus 26.1% in the Late ART group (P < 0.001 at log rank 
test) (Figure 1C).
We analyzed predictors of time to first-line ART regimen discontinuation by Cox regression anal-
ysis (Table 5). At univariate analysis, patients starting early ART showed a higher risk of discon-
tinuation (HR 2.34 [95% CI 1.55-3.52], P < 0.001), while those in Fiebig stages I-II showed a lower 
risk (HR 0.57 [95% CI 0.35-0.93], P = 0.024). However, at multivariate analysis, after adjustment 
for male gender, time from last negative HIV test, the first ART regimen including > 3 drugs, and 
calendar year, the association between early ART or Fiebig stage and regimen discontinuation was 
no longer demonstrated. The only independent predictor of first-line regimen discontinuation 
was initiating antiretroviral treatment with regimens including > 3 drugs (HR 1.88 [95% CI 1.13-
3.13], P = 0.015).
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Table 5. Predictors of time to first-line regimen discontinuation (Cox regression analysis) 
(n = 162)
Univariate analysis Multivariate analysis
HR (95% CI) P aHR (95% CI) P
Age, years (per 10 years increase) 1.02 (0.88-1.18) 0.832
Male gender 1.92 (1.15-3.20) 0.013 2.56 (0.92-7.09) 0.072
Risk factor:
    Heterosexual
    Homo/bisexual
    IDU
    Other/unknown
Ref.
1.35 (0.93-1.97)
2.54 (0.99-6.50)
1.55 (0.87-2.77)
0.119
0.053
0.142
HBsAg+ 0.80 (0.33-1.97) 0.627
HCV coinfection 1.46 (0.68-3.12) 0.334
Months from last negative HIV test, 
(per 1 month increase)
1.01 (1.00-1.01) 0.049 1.00 (1.00-1.01) 0.242
Fiebig stage: I-II vs III-V 0.57 (0.35-0.93) 0.024 0.66 (0.33-1.33) 0.246
Symptomatic acute HIV infection 1.03 (0.96-1.10) 0.486
CDC Stage C 0.69 (0.17-2.90) 0.617
Concomitant STD 0.98 (0.51-1.87) 0.947
Early (< 3 months from BL) ART 
initiation
2.34 (1.55-3.52) < 0.001 1.37 (0.72-2.62) 0.339
First ART regimen including:
    NRTI
    NNRTI
    PI
    InSTI
    Entry inhibitor
0.86 (0.21-3.48)
0.49 (0.31-0.76)
1.66 (1.12-2.47)
2.43 (1.71-3.45)
2.36 (1.50-3.73)
0.830
0.002
0.012
< 0.001
< 0.001
First ART regimen including > 3 
drugs
2.98 (2.09-4.25) < 0.001 1.94 (1.16-3.25) 0.012
Laboratory results at first ART initi-
ation:
    CD4, cells/µL (per 100cell/µL 
increase)
1.01 (0.93-1.10) 0.765
    CD8, cells/µL (per 100cell/µL 
increase)
0.99 (0.98-1.01) 0.402
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    CD4/CD8 ≥ 1 0.84 (0.43-1.66) 0.624
    HIV-RNA, log10 copies/mL (per 
1log10 copies/mL increase)
1.18 (0.97-1.43) 0.100
Year of diagnosis, 2012-2014 vs 2008-
2011
1.32 (1.18-1.48) < 0.001 1.26 (0.72-2.20) 0.428
Abbreviations: IDU Intravenous Drug User; CDC Centers for Disease Control; STD Sexually Transmit-
ted Diseases; ART Antiretroviral Therapy; BL Baseline; NRTI Nucleoside Reverse Transcriptase Inhibitor; 
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors; PI Protease Inhibitor; InSTI Integrase Strand 
Transfer Inhibitor.
DISCUSSION
This is the first Italian multicentric study aimed to evaluate the use and the effect of early antiret-
roviral treatment of AEHI on a large observational cohort. The results of our study confirm that, 
during AEHI, early ART leads to enhanced rates of optimal immunological recovery compared 
to late ART, with no significant impact of this strategy on time to virological response or first-line 
regimen discontinuation. Conversely, Fiebig stage at diagnosis and the number of drugs included 
in the first ART regimen (intensified versus standard regimen) were not found to affect immuno-
logical recovery. Moreover, our analysis allowed us to define predictors of virological response in 
the setting of AEHI. Pre-ART CD4+/CD8+ ratio, together with HIV replication levels, are inde-
pendently associated with time to virological suppression, giving new insights into the interplay 
between immune function and virological control. The possible role of HBV-coinfection as a 
factor influencing a more rapid virological suppression needs to be clarified through prospective 
studies using standardized ART regimens in high endemicity settings.
In accordance with recent updates in international guidelines [23], in our real-life setting we con-
firmed a shift towards an early start of antiretroviral therapy during AEHI in recent years (2012-
2014) compared to previous years (2008-2011), when nearly half of patients with AEHI started 
ART after 3 months from diagnosis. ART regimens prescribed as first-line treatment significantly 
differed between patients treated early or late after AEHI diagnosis; indeed, protease inhibitors 
and integrase inhibitors were more frequently used in the Early ART group, while NNRTI were 
mainly prescribed in the Late ART group. These differences in therapeutic choices can be ex-
plained by the more recent introduction of integrase inhibitors as the preferred first-line ART 
regimen in international guidelines and by the high genetic barrier of protease inhibitors allowing 
their use in early treatment of AEHI, while waiting results of genotypic resistance testing. 
Despite the fact that data from clinical trials failed to demonstrate a clear clinical benefit of an in-
tensified, multi-target ART as opposed to 3-drug standard regimens during AEHI [24-27], in our 
cohort we described a fairly frequent use of regimens including more than 3 drugs in early-treat-
ed AEHI patients (38.8% of subjects). Of note, in our cohort, early treatment was associated with 
greater risk of changes in ART regimen at univariate analysis, but patients who started early were 
also treated more frequently with regimens containing more than 3 drugs. Indeed, at multivariate 
analysis, after adjusting for the number of drugs in the first-line regimen, early treatment did not 
confirm an association with treatment discontinuation. Nevertheless, we recognized that a first 
ART regimen including more than 3 drugs was independently associated with a higher probabil-
Pathogens and Immunity - Vol 5, No 1
www.PaiJournal.com
26
ity of first ART regimen discontinuation, thus reflecting the common approach to switch to sim-
plified regimens after a first intensified phase, which led to viral suppression, or tolerability issues.
Early antiretroviral treatment in AEHI and a less compromised immunological status at ART 
initiation emerged as independent predictors of optimal immunological recovery (defined as re-
constitution of absolute and percentage CD4 T-cell count, CD4/CD8 ratio), while Fiebig stage at 
diagnosis or administration of intensified regimens with more than 3 drugs did not show an effect 
on subsequent immunological outcome. To date, few studies have investigated the evolution of 
CD4/CD8 ratios in patients initiating ART close to infection. A sub-study [28] of the SPARTAC 
trial [29] investigating factors associated with time from ART initiation to CD4/CD8 ratio nor-
malization, showed a higher probability of CD4/CD8 ratio normalization when ART was initiated 
closer to seroconversion (within 6 months from seroconversion). More recently, very early ART 
(initiated within 40 days of the estimated date of infection) in Fiebig I-II acutely infected patients 
was demonstrated to be associated with a significant increase in CD4/CD8 ratios [14], and the 
1-year longitudinal evaluation of 83 patients starting ART within 120 days after the estimated date 
of infection displayed a better reconstitution of CD4/CD8 ratio compared to chronically infected 
subjects [15]. Here we confirmed that early ART, defined as ART introduced within 3 months 
from AEHI, has a beneficial effect on immune function in a large setting of patients, which were 
accurately defined according to Fiebig stage and thus excluded recent seroconverters, who were 
included in some of the previous analysis.
In our retrospective observational study, timing of ART initiation or types of antiretroviral drugs 
included in first-line regimens did not influence the achievement of virological suppression. 
Interestingly, we found that HBV coinfection, recent year of diagnosis, and a normal CD4/CD8 
ratio at baseline (> 1) were independent predictors of time to virological suppression. On the 
other hand, as expected, higher HIV-RNA levels were associated with a longer time to virologi-
cal suppression. The link between year of diagnosis and time to virological suppression could be 
explained by the recent wide use of antivirals able to rapidly reduce viral replication (ie, integrase 
inhibitors). This was recently observed in a similar study performed on acutely infected HIV 
patients who mostly began ART at their first medical appointment [30]. Similarly, patients with 
active HBV infection could have been treated with a tenofovir-based regimen more frequently 
than uninfected ones, thus masking a difference in the use of ART regimen. Indeed, much of the 
literature showed no difference between HIV monoinfected and HIV/HBV coinfected patients in 
achieving undetectable HIV-RNA after ART-initiation [31, 32], while recent observations report-
ed a faster immune-reconstitution in HIV/HBV coinfected patients with high HBV-DNA viral 
load [33].
It is worth noting that we evidenced a role for baseline CD4/CD8 ratio as a predictor of time to 
virological suppression, suggesting that a preserved balance between T helper and T cytotoxic 
cells could provide a significant contribution in containing viral replication. 
In the setting of untreated chronic HIV infection, CD4/CD8 ratio predicts time to AIDS devel-
opment [34]. During treated HIV infection, expansion of CD8+ T cells (leading to low CD4/CD8 
ratio) identifies a subgroup of individuals with a number of immunological abnormalities, name-
ly an increased innate and adaptive immune activation, an immunosenescent phenotype, and a 
higher risk of morbidity/mortality [35]. In the setting of early acute HIV infection, an inverse cor-
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relation between HIV-1 DNA content and CD4/CD8 ratio was found, suggesting the potential use 
of normalized CD4/CD8 ratio as a valuable biomarker to identify individuals with  a smaller size 
of HIV reservoir [36]. Moreover, some observations suggest that pre-ART CD4/CD8 ratio influ-
ences time to viral load rebound after analytical treatment interruption in acutely treated individ-
uals [37, 38]. Our results showing a correlation between CD4/CD8 ratio pre-ART initiation and 
time to virological suppression suggest that T-cell immune exhaustion rapidly established after 
acute HIV infection can influence virological control. Further studies characterizing HIV-specific 
T cells, innate/adaptive activation, and immune exhaustion parameters in AEHI patients treated 
with standardized ART-regimens at different Fiebig stages could better define the real impact of 
these immunological abnormalities on virological control.
Our study, due to its observational nature, has several limitations. First, the availability of im-
munological data during follow-up was limited to less than 60% of our cohort, thus reducing the 
power of our population study. Second, it was not possible to adjust for unmeasured confounders, 
such as CMV infection, that recently emerged as an important predictor of CD4/CD8 ratio nor-
malization [39]. Third, we lack data about HIV-DNA levels, thus we could not evaluate if tim-
ing or number of agents included in the ART regimen or immune parameters at baseline could 
influence the size of viral reservoir. A previous study [22] included the reduction of HIV-DNA in 
PBMCs in the definition of optimal viro-immunological recovery in ART-treated acutely infected 
patients, and the study demonstrated a higher probability of reaching optimal viro-immunolog-
ical recovery in patients starting ART during AEHI compared with late ART, thus underlining a 
possible link between HIV-DNA limitation and immune-reconstitution during AEHI. 
In conclusion, in a large observational setting, we observed that early ART during AEHI was able 
to enhance the achievement of optimal immune recovery in a significant way, which is rarely ob-
served when ART is started during chronic infection, thus confirming the benefit of this strategy 
against the potential disadvantages of early continuous treatment. Moreover, we identified predic-
tors of time to virological response in a well-characterized setting of AEHI, showing an indepen-
dent role for CD4/CD8 ratio and giving insight into the research of new immunological markers 
to be considered in future algorithm selection of strategies for the cure of HIV. 
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